Cancer driver mutations found in Alzheimer's microglia
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Boston Children's Hospital researchers, analyzing 149 cancer-driving genes in brain tissue from 190 Alzheimer's patients and 121 healthy controls, found that microglia in Alzheimer's brains carry significantly more single-letter DNA mutations, with five specific cancer driver genes hit repeatedly.
- The study, published in Cell, was led by Christopher Walsh, MD, PhD, with collaborators Alice Eunjung Lee, PhD, and August Yue Huang, PhD — all Harvard Medical School faculty and Broad Institute associate members.
- Blood samples from the same Alzheimer's patients carried the identical cancer-associated mutations found in their brain microglia, a result Huang called 'a totally unexpected finding that suggests a totally new mechanism for Alzheimer's disease pathogenesis.'
- The team proposes that aging or injury weakens the blood-brain barrier, letting mutated immune cells from the bloodstream enter the brain, transform into microglia-like cells, and create a more inflammatory environment that damages neurons.
- A follow-up bioRxiv preprint by Huang and Lee found that cancer driver mutations detected in blood increased Alzheimer's risk independently of APOE4, the best-established genetic risk factor for the disease.
- Walsh said the overlap with blood cancers like lymphoma and leukemia means 'we have a lot of drugs to fight cancer and some of them might be useful therapeutically for Alzheimer's disease.'
- The collaboration with the Icahn School of Medicine at Mount Sinai was funded by HHMI, the National Institute on Aging, the NIH Common Fund's SMaHT consortium, and the Suh Kyungbae Foundation.
Why it matters: The finding recasts Alzheimer's as partly driven by the same mutations behind blood cancers, meaning a future blood-based genetic screen could flag at-risk people without sampling brain tissue. Walsh explicitly pointed to existing cancer drugs as candidate Alzheimer's therapies, giving developers a repurposing path that sidesteps building new molecular tools from scratch.
Ask SkimNews
